Skip to content
HowShorted

Corbus Pharmaceuticals Holdings, Inc. short interest in 2024

In 2024, Corbus Pharmaceuticals Holdings, Inc.'s disclosed short interest ran from 0.63% of shares outstanding on 12 Jan 2024 to 19.79% on 31 Dec 2024, a change of +19.16 percentage points. The year's high was 22.83% on 15 Oct 2024 and its low 0.63% on 12 Jan 2024, averaging 11.11% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.76 days on 29 Nov 2024. Full history: Corbus Pharmaceuticals Holdings, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Corbus Pharmaceuticals Holdings, Inc. in 2024

2024 in figures

Start of year
0.63% (12 Jan 2024)
End of year
19.79% (31 Dec 2024)
Change
+19.16 pp
High
22.83% (15 Oct 2024)
Low
0.63% (12 Jan 2024)
Average
11.11%
Highest days to cover
11.76 (29 Nov 2024)
SEC filings marked
8

Every report in 2024

Corbus Pharmaceuticals Holdings, Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20240.63%1.22
29 Feb 20241.38%1.00
15 Mar 20243.85%1.0010-K filed, results (8-K)
28 Mar 20244.53%1.96
15 Apr 20245.94%2.94
30 Apr 20246.77%3.13
15 May 20244.80%2.0810-Q filed, results (8-K)
31 May 20243.45%2.10
14 Jun 20245.84%2.12
28 Jun 20247.83%1.76
15 Jul 202411.08%3.99
31 Jul 202411.21%4.91
15 Aug 202410.10%4.3010-Q filed, results (8-K)
30 Aug 202410.43%4.75
13 Sep 202410.45%5.19
30 Sep 202421.60%1.25
15 Oct 202422.83%5.36
31 Oct 202419.75%6.69
15 Nov 202419.72%6.2910-Q filed, results (8-K)
29 Nov 202420.57%11.76
13 Dec 202421.76%8.48
31 Dec 202419.79%7.03

See also: Corbus Pharmaceuticals Holdings, Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.